Fusion protein based on Grb2-SH2 domain for cancer therapy

Biochemical and Biophysical Research Communications
Yuriko SaitoTsuneo Saga

Abstract

Epidermal growth factor receptor (EGFR) is one of the very attractive targets for cancer therapy. In this study, we generated fusion proteins containing one or two Src-homology 2 (SH2) domains of growth factor receptor bound protein 2 (Grb2), which bind to phosphorylated EGFR, added with HIV-1 transactivating transcription for cell membrane penetration (termed TSF and TSSF, respectively). We examined if they can interfere Grb2-mediated signaling pathway and suppress tumor growth as expected from the lack of SH3 domain, which is necessary to intermediate EGFR-Grb2 cell signaling, in the fusion proteins. The transduction efficiency of TSSF was similar to that of TSF, but the binding activity of TSSF to EGFR was higher than that of TSF. Treatment of EGFR-overexpressing cells showed that TSSF decreased p42-ERK phosphorylation, while TSF did not. Both the proteins delayed cell growth but did not induce cell death in culture. TSSF also significantly suppressed tumor growth in vivo under consecutive administration. In conclusion, TSSF showed an ability to inhibit EGFR-Grb2 signaling and could have a potential to treat EGFR-activated cancer.

References

Oct 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·K MatuokaT Takenawa
Sep 2, 1999·International Journal of Cancer. Journal International Du Cancer·B GayJ Schoepfer
Jun 28, 2001·Oncogene·J Mendelsohn, J Baselga
Mar 22, 2003·Experimental Cell Research·H Steven Wiley
May 26, 2004·Biochemical and Biophysical Research Communications·Robert Roskoski
Dec 2, 2004·Nature Reviews. Cancer·Roy S HerbstJosé Baselga
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Jul 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Toshimi TakanoTomohide Tamura
Sep 29, 2005·PLoS Medicine·Heidi GreulichMatthew Meyerson
Dec 27, 2005·Gene·Nicola NormannoDavid S Salomon
Mar 7, 2006·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hiroshi HaradaMasahiro Hiraoka
Aug 8, 2006·Seminars in Oncology·John Mendelsohn, Jose Baselga
Aug 31, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Gisela TünnemannM Cristina Cardoso
Apr 24, 2007·The Journal of Biological Chemistry·Ning LiLisa A Elferink
Jan 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Cai-Hong YunMichael J Eck
Jul 3, 2010·International Journal of Oncology·Yuriko SaitoTsuneo Saga

❮ Previous
Next ❯

Citations

Nov 9, 2012·Cell Communication and Signaling : CCS·Tomonori KanekoShawn Sc Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.